A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Inclusion Criteria: * Subjects with histopathologically confirmed diagnosis of advanced breast, gastric, head and neck, liver and non-small cell lung cancer. * For subjects with non-small cell lung cancer only: * Most recent treatment must be erlotinib and subjects must have had a radiographic partial or complete response to treatment as defined by RECIST criteria and should be currently progressing after the documented response. * A documented mutation in EGFR exons 19 or 21 * Subjects must have no further standard of care options or have refused standard therapy * Measurable or evaluable disease * Age ≥ 18 years * ECOG performance \< 2 * Life expectancy ≥ 3 months * If female, neither pregnant or lactating * If of child bearing potential, must use adequate birth control * Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; * Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60mL/min/1.73m2 * Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver metastases, the AST/ALT may be ≤ 5x ULN * Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation * Serum magnesium and potassium within normal limits (may use supplements to achieve normal values) * Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg prednisone/day or its equivalent dose of steroids * Able to render informed consent and to follow protocol requirements. Exclusion Criteria: * Anticancer therapy within 4 weeks of study entry. * Use of investigational agent(s) within 30 days of study entry * History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment. * Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Subjects with liver cancer and hepatitis may be eligible.